Home › Funds › Vestal Point Capital, LP › EVMN
Vestal Point Capital, LP position in EVMN
EVOMMUNE INC · Health Care
Vestal Point Capital, LP reported holding 1,250,000 shares of EVMN (EVOMMUNE INC) in its Q3 2026 13F filing — a position valued at US$10.3M, representing 0.27% of its reported portfolio and ranking #38 among its reported holdings. Vestal Point Capital, LP has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's EVMN position evolved
Vestal Point Capital, LP first disclosed a stake in EVMN in Q2 2026 at 1,000,000 shares (US$13.3M). Across 2 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 1,250,000 shares valued at US$10.3M — an increase of 250,000 shares quarter over quarter.. Notable position changes include a 25% increase in Q3 2026 (shares fell 14% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 1.00M | $13.29M | New |
| Q3 2026 | 1.25M | $10.32M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About EVMN and 13F data
EVMN (EVOMMUNE INC) is a Health Care company. 80 other funds we track also report a position in EVMN — the largest reported positions include EQT Fund Management S.a r.l. (US$43.7M), SymBiosis Capital Partners, LLC (US$29.4M), RA CAPITAL MANAGEMENT, L.P. (US$28.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding EVMN
- EQT Fund Management S.a r.l. 5.29M sh · $43.68M · Q3 2026
- SymBiosis Capital Partners, LLC 1.28M sh · $29.45M · Q1 2026
- RA CAPITAL MANAGEMENT, L.P. 3.49M sh · $28.87M · Q3 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.93M sh · $15.92M · Q3 2026
- Nan Fung Group Holdings Ltd 1.44M sh · $11.90M · Q3 2026
- Defilade Capital Management, L.P. 1.43M sh · $11.82M · Q3 2026
- Kynam Capital Management, LP 1.20M sh · $9.91M · Q3 2026
- SILVERARC CAPITAL MANAGEMENT, LLC 594.03K sh · $4.91M · Q3 2026
- Velan Capital Investment Management LP 456.25K sh · $3.77M · Q3 2026
- GREAT POINT PARTNERS LLC 325.00K sh · $2.68M · Q3 2026
- NEXTBio Capital Management LP 119.06K sh · $983.46K · Q3 2026
- Andera Partners 97.36K sh · $804.21K · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held EVMN?
Vestal Point Capital, LP has disclosed EVMN holdings in 2 of the last 2 reported quarters, going back to Q2 2026.
What is Vestal Point Capital, LP's current position in EVMN?
As of Q3 2026, Vestal Point Capital, LP holds 1.25M shares of EVMN (EVOMMUNE INC), valued at $10.32M, representing 0.27% of its reported portfolio and ranking #38.
Has Vestal Point Capital, LP been buying or selling EVMN?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP increased its position in EVMN.
Which other funds hold EVMN?
Other major institutional holders of EVMN include EQT Fund Management S.a r.l., SymBiosis Capital Partners, LLC, RA CAPITAL MANAGEMENT, L.P., among 80 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.